LoginSignup
Mind Medicine logo

Mind Medicine Stock

StockStock
ISIN: CA60255C8850
Ticker: MNMD
CA60255C8850
MNMD

Price

Frequently asked questions

What is Mind Medicine's market capitalization?

The market capitalization of Mind Medicine is $600.59M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Mind Medicine?

Mind Medicine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.987. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Mind Medicine's stock?

Currently, 9 analysts cover Mind Medicine's stock, with a consensus target price of $24.25. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Mind Medicine?

Mind Medicine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$92.33M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Mind Medicine?

Mind Medicine has a free cash flow of -$74.34M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Mind Medicine's stock?

The 5-year beta for Mind Medicine is -6.67. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Mind Medicine have, and what sector and industry does it belong to?

Mind Medicine employs approximately 57 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Mind Medicine's shares?

The free float of Mind Medicine is 72.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $600.59M

5Y beta

 -6.67

EPS (TTM)

 -$1.987

Free Float

 72.50M

EBITDA (TTM)

 -$92.33M

Free Cashflow (TTM)

 -$74.34M

Pricing

1D span
$8.128$8.733
52W span
$2.42$12.22

Analyst Ratings

The price target is $24.25 and the stock is covered by 9 analysts.

Buy

8

Hold

1

Sell

0

Information

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

57

Biotechnology & Drugs

Health Care

Identifier

ISIN

CA60255C8850

Primary Ticker

MNMD

Knockouts

Join the conversation
Sign upLogin